Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Clemow

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Inflammatory Bowel Diseases|March 4, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension studyBruce E Sands, David B Clemow, Geert D'Haens, et al.
Journal of Patient-Reported Outcomes|July 1, 2025
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumabDavid B Clemow, Marla C Dubinsky, Simin K Baygani, et al.
Expert Review of Neurotherapeutics|October 22, 2015
Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review studyDavid B Clemow, Oren W Mason, Elias H Sarkis, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Medical Writing Competency Model - Section 1: Functions, Tasks, and ActivitiesDavid B Clemow, Bertil Wagner, Christopher Marshallsay, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Medical Writing Competency Model - Section 2: Knowledge, Skills, Abilities, and BehaviorsDavid B Clemow, Bertil Wagner, Christopher Marshallsay, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Inflammatory Bowel Diseases|March 4, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension studyBruce E Sands, David B Clemow, Geert D'Haens, et al.
Journal of Patient-Reported Outcomes|July 1, 2025
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumabDavid B Clemow, Marla C Dubinsky, Simin K Baygani, et al.
Expert Review of Neurotherapeutics|October 22, 2015
Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review studyDavid B Clemow, Oren W Mason, Elias H Sarkis, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Medical Writing Competency Model - Section 1: Functions, Tasks, and ActivitiesDavid B Clemow, Bertil Wagner, Christopher Marshallsay, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Medical Writing Competency Model - Section 2: Knowledge, Skills, Abilities, and BehaviorsDavid B Clemow, Bertil Wagner, Christopher Marshallsay, et al.
Pageof 3